Brain Tumor Pathology最新文献_第9页

Implications of immune cells in oncolytic herpes simplex virotherapy for glioma 免疫细胞在胶质瘤溶瘤性单纯疱疹病毒治疗中的意义

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-04-01 DOI: 10.1007/s10014-022-00431-8

Yoshihiro Otani, J. Yoo, Toshihiko Shimizu, K. Kurozumi, I. Date, B. Kaur

引用次数: 7

Ribosomal proteins induce stem cell-like characteristics in glioma cells as an “extra-ribosomal function” 核糖体蛋白作为“核糖体外功能”诱导胶质瘤细胞的干细胞样特征

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-04-01 DOI: 10.1007/s10014-022-00434-5

T. Hide, Ichiyo Shibahara, M. Inukai, Ryota Shigeeda, Y. Shirakawa, H. Jono, N. Shinojima, A. Mukasa, T. Kumabe

引用次数: 2

Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications 三个解剖部位室管膜瘤的分子亚组及其预后意义

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-03-29 DOI: 10.1007/s10014-022-00429-2

Dheeraj Chinnam, K. Gupta, T. Kiran, Aastha Saraswati, P. Salunke, R. Madan, Narendra Kumar, B. Radotra

引用次数: 2

The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas 低级别胶质瘤的少突胶质组织学特征不能独立预测患者预后

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-03-15 DOI: 10.1007/s10014-022-00426-5

E. Pareira, M. Shibuya, Kentaro Ohara, Yu Nakagawa, Tokunori Kanazawa, Dai Kamamoto, Y. Kato, Eri Arai, E. Aimono, Kazunari Yoshida, H. Nishihara, Y. Kanai, H. Sasaki

引用次数: 1

Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature. 中枢神经系统VCL-ALK融合的上皮样炎性肌纤维母细胞肉瘤1例报告及文献复习。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-01-01 Epub Date: 2021-11-06 DOI: 10.1007/s10014-021-00416-z

Shefali Chopra, Nolan Maloney, Wei Lien Wang

引用次数: 8

Molecular subtyping of ependymoma and prognostic impact of Ki-67. 室管膜瘤分子分型及Ki-67对预后的影响。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-01-01 Epub Date: 2021-11-23 DOI: 10.1007/s10014-021-00417-y

Ka Young Lim, Kwanghoon Lee, Yumi Shim, Jin Woo Park, Hyunhee Kim, Jeongwan Kang, Jae Kyung Won, Seung-Ki Kim, Ji Hoon Phi, Chul-Kee Park, Chun-Kee Chung, Hongseok Yun, Sung-Hye Park

{"title":"Molecular subtyping of ependymoma and prognostic impact of Ki-67.","authors":"Ka Young Lim, Kwanghoon Lee, Yumi Shim, Jin Woo Park, Hyunhee Kim, Jeongwan Kang, Jae Kyung Won, Seung-Ki Kim, Ji Hoon Phi, Chul-Kee Park, Chun-Kee Chung, Hongseok Yun, Sung-Hye Park","doi":"10.1007/s10014-021-00417-y","DOIUrl":"https://doi.org/10.1007/s10014-021-00417-y","url":null,"abstract":"Although ependymomas (EPNs) have similar histopathology, they are heterogeneous tumors with diverse immunophenotypes, genetics, epigenetics, and different clinical behavior according to anatomical locations. We reclassified 141 primary EPNs from a single institute with immunohistochemistry (IHC) and next-generation sequencing (NGS). Supratentorial (ST), posterior fossa (PF), and spinal (SP) EPNs comprised 12%, 41%, and 47% of our cohort, respectively. Fusion genes were found only in ST-EPNs except for one SP-EPN with ZFTA-YAP1 fusion, NF2 gene alterations were found in SP-EPNs, but no driver gene was present in PF-EPNs. Surrogate IHC markers revealed high concordance rates between L1CAM and ZFTA-fusion and H3K27me3 loss or EZHIP overexpression was used for PFA-EPNs. The 7% cut-off of Ki-67 was sufficient to classify EPNs into two-tiered grades at all anatomical locations. Multivariate analysis also delineated that a Ki-67 index was the only independent prognostic factor in both overall and progression-free survivals. The gain of chromosome 1q and CDKN2A/2B deletion were associated with poor outcomes, such as multiple recurrences or extracranial metastases. In this study, we propose a cost-effective schematic diagnostic flow of EPNs by the anatomical location, three biomarkers (L1CAM, H3K27me3, and EZHIP), and a cut-off of a 7% Ki-67 labeling index.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"39 1","pages":"1-13"},"PeriodicalIF":3.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39650799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. IDH1-R132H、ATRX和/或p53免疫组化对2/3级胶质瘤分子亚分类的可靠性

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-01-01 Epub Date: 2021-11-26 DOI: 10.1007/s10014-021-00418-x

Tomohide Nishikawa, Reiko Watanabe, Yotaro Kitano, Akane Yamamichi, Kazuya Motomura, Fumiharu Ohka, Kosuke Aoki, Masaki Hirano, Akira Kato, Junya Yamaguchi, Sachi Maeda, Yuji Kibe, Ryuta Saito, Toshihiko Wakabayashi, Yukinari Kato, Shuta Sato, Tomoyoshi Ogino, Atsushi Natsume, Ichiro Ito

{"title":"Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.","authors":"Tomohide Nishikawa, Reiko Watanabe, Yotaro Kitano, Akane Yamamichi, Kazuya Motomura, Fumiharu Ohka, Kosuke Aoki, Masaki Hirano, Akira Kato, Junya Yamaguchi, Sachi Maeda, Yuji Kibe, Ryuta Saito, Toshihiko Wakabayashi, Yukinari Kato, Shuta Sato, Tomoyoshi Ogino, Atsushi Natsume, Ichiro Ito","doi":"10.1007/s10014-021-00418-x","DOIUrl":"https://doi.org/10.1007/s10014-021-00418-x","url":null,"abstract":"Since the World Health Organization 2016 classification (2016 WHO), genetic status has been incorporated into the diagnosis of Grade 2/3 gliomas (lower-grade gliomas). Therefore, immunohistochemistry (IHC) of IDH1-R132H, ATRX, and p53 have been used in place of genetic status. We report the associations between histological findings, IHC, and genetic status. We performed IHC of IDH1-R132H, ATRX, and p53 in 76 lower-grade gliomas and discussed its validity based on the 2016 WHO and the upcoming 2021 WHO classification. The sensitivity and specificity of anti-ATRX, p53, and IDH1-R132H IHC were 40.9%/98.1%, 78.6%/85.4%, and 90.5%/84.6%, respectively. Among 21 IDH1-mutant gliomas without 1p/19q codeletion, two gliomas (9.5%) mimicked the so-called classic for oligodendroglioma (CFO) in their morphology. Of the 42 gliomas with 1p/19q codeletion, four cases were difficult to diagnose as oligodendroglioma through morphological examination. Moreover, there were three confusing cases with ATRX mutations but with retained ATRX-IHC positivity. The lessons learned from this study are as follows: (1) ATRX-IHC and p53-IHC should be supplementary to morphological diagnosis, (2) rare IDH mutations other than IDH1 R132H should be considered, and (3) there is no complete alternative test to detect molecular features of glioblastoma under the 2021 WHO classification.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"39 1","pages":"14-24"},"PeriodicalIF":3.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39928455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement. 中枢神经系统alk阴性间变性大细胞淋巴瘤伴IRF4/DUSP22重排。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-01-01 Epub Date: 2021-11-18 DOI: 10.1007/s10014-021-00415-0

Shino Magaki, Radha Satyadev, Zesheng Chen, Kathryn S Yung, Harry V Vinters, Marsha C Kinney, Jonathan W Said

{"title":"Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.","authors":"Shino Magaki, Radha Satyadev, Zesheng Chen, Kathryn S Yung, Harry V Vinters, Marsha C Kinney, Jonathan W Said","doi":"10.1007/s10014-021-00415-0","DOIUrl":"https://doi.org/10.1007/s10014-021-00415-0","url":null,"abstract":"Anaplastic large cell lymphomas (ALCL) are mature T-cell neoplasms, approximately half of which harbor rearrangements of the ALK gene that confer a good prognosis. Recent studies have demonstrated that a significant proportion of ALK-negative ALCLs demonstrate rearrangements of the IRF4/DUSP22 locus that also are typically associated with a favorable prognosis. ALCL with primary involvement of the central nervous system (CNS) is extremely rare. We report what may be the first case of ALK-negative ALCL with IRF4/DUSP22 rearrangement involving the brain in a 55-year-old man. Magnetic resonance imaging demonstrated signal abnormalities in the periventricular region, corpus callosum and cingulate gyrus. Biopsy revealed a diffuse parenchymal and angiocentric infiltrate of CD30-positive cells that showed IRF4/DUSP22 rearrangement by fluorescence in situ hybridization. We also review the clinical and pathologic features of primary CNS ALK-negative ALCLs in the literature and highlight the need for awareness of this entity to optimize appropriate management.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"39 1","pages":"25-34"},"PeriodicalIF":3.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39743867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Correction to: Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature. 纠正:中枢神经系统VCL-ALK融合的上皮样炎性肌纤维母细胞肉瘤:病例报告及文献综述。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-01-01 DOI: 10.1007/s10014-021-00425-y

Shefali Chopra, Nolan Maloney, Wei Lien Wang

引用次数: 0

Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma. 重新审视vimentin:成人型弥漫性胶质瘤中分子定义的少突胶质细胞瘤的阴性替代标记物。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2021-10-01 Epub Date: 2021-08-02 DOI: 10.1007/s10014-021-00411-4

Seong-Ik Kim, Kwanghoon Lee, Jeongmo Bae, Sungyoung Lee, Hongseok Yun, Chul-Kee Park, Seung Hong Choi, Christopher Alec Maquiling, Sung-Hye Park, Jae-Kyung Won

{"title":"Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma.","authors":"Seong-Ik Kim, Kwanghoon Lee, Jeongmo Bae, Sungyoung Lee, Hongseok Yun, Chul-Kee Park, Seung Hong Choi, Christopher Alec Maquiling, Sung-Hye Park, Jae-Kyung Won","doi":"10.1007/s10014-021-00411-4","DOIUrl":"https://doi.org/10.1007/s10014-021-00411-4","url":null,"abstract":"Vimentin is a marker of epithelial-mesenchymal transformation and indicates poor prognosis in various cancers, but its role in diffuse gliomas remains unknown. We investigated the vimentin expression of diffuse gliomas according to the upcoming 2021 WHO classification, its variations due to mutational status, and its prognostic effects. We analyzed vimentin immunohistochemistry in 315 gliomas: a test set (n = 164) and a validation set (n = 151). RNA-seq and mutational information from The Cancer Genome Atlas (TCGA, n = 422) were also used for validation. Vimentin was diffusely positive in astrocytic tumors but negative in oligodendroglial tumors (ODGs) and its expression was significantly higher in isocitrate dehydrogenase (IDH) wild-type tumors. High vimentin expression was correlated with poor prognosis (hazard ratio [HR]: 5.99), but it was dependent on the new WHO grade which reflects both histologic features and genetics (HR: 1.28). Using the significant difference in vimentin expression between ODGs and astrocytic tumors, the positive and negative predictive values of the vimentin-based diagnosis for ODGs were 93.5% and 97.8% in the validation set. Along with additional alpha-thalassemia/mental retardation, X-linked (ATRX) immunohistostaining, the values were 98.3% and 97.8%, respectively. Vimentin is a useful ancillary marker for identifying ODGs when combined with routine histochemistry markers.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"38 4","pages":"271-282"},"PeriodicalIF":3.3,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39267959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2